Daewoong Pharma, a leading South Korean pharmaceutical company, has reportedly signed a memorandum of understanding (MoU) with China Meheco International, a move that will facilitate the export of Daewoong’s pharmaceutical products into the Chinese market. This comprehensive agreement encompasses the entire portfolio of Daewoong’s products, including their innovative in-house novel drugs.
Building on Previous Partnership
The MoU comes on the heels of a distribution and sales contract signed between Daewoong and Meheco in August of this year, which was specifically focused on the local Chinese manufacturing and distribution of Daewoong’s antacid therapy, Newranta. The partnership with Meheco is aimed at expediting the introduction of new therapies to the Chinese market by leveraging Meheco’s expertise in supporting the importation of externally manufactured products.
Product Approvals and Pipeline in China
According to the public data, Daewoong currently holds four valid product approvals in China. In June, the company filed a new drug application (NDA) with Chinese authorities for Fexuclu/Abcito (fexuprazan) in a 40mg dosage form. Fexuclu is an in-house developed potassium-competitive acid blocker (P-CAB) and represents a new generation therapy for the treatment of gastroesophageal reflux disease (GERD). Additionally, Daewoong is developing enavogliflozin, a novel SGLT2 inhibitor, for the Chinese market.- Flcube.com
